Core Viewpoint - Adma Biologics (ADMA) has seen a 5.8% increase in share price over the past four weeks, closing at $19.92, with analysts suggesting a potential upside of 25.5% based on a mean price target of $25 [1] Price Targets - The average price target for ADMA ranges from a low of $24 to a high of $26, with a standard deviation of $0.82, indicating a relatively tight clustering of estimates [2] - The lowest estimate suggests a 20.5% increase from the current price, while the highest estimate indicates a 30.5% upside [2] Analyst Sentiment - Analysts show strong agreement regarding ADMA's potential for better earnings, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][9] - The Zacks Consensus Estimate for the current year has risen by 5.4% over the past month, with three estimates increasing and no negative revisions [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock price movements, the direction indicated by these targets can serve as a useful guide for further research [12]

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 20.7% in the past four weeks, closing at $19.04, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $25, representing a 31.3% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.82, where the lowest estimate of $24 indicates a 26.1% increase, and the highest estimate suggests a 36.6% surge to $26 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [7] Earnings Estimates and Market Sentiment - Analysts are optimistic about ADMA's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, three earnings estimates for ADMA have been revised upward, leading to a 5.4% increase in the Zacks Consensus Estimate [10] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can mislead, as empirical research shows that they rarely indicate actual stock price movements [5] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [8][12]

LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ: ADMA) for violations of the securities laws.According to the Complaint, the Company made false and misleading statements to the market. ADMA Biologics admitted the abrupt resignation of its independent outside auditor, CohnReznick LLP., on October 9, 2024. The Company ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Grossman – President and Chief Executive Officer Brad Tade – Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Anthony Petrone – Mizuho Group Gary Nachman – Raymond James Operator Thank you for standing by. My name is Celine and I will be your conference operator ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.08 per share when it actually produced earnings of $0.13, delivering a surprise of 62.50%. Over the last ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (Sta ...

Exhibit 99.1 ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update 3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA(1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively FY 2024 and 2025 GAAP Net Income Gui ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

ADMA Biologics (ADMA) is scheduled to report third-quarter 2024 results on Nov. 7, after market close.The Zacks Consensus Estimate for sales and earnings is pegged at $107.25 million and 13 cents per share, respectively.Image Source: Zacks Investment ResearchFind the latest EPS estimates and surprises on Zacks Earnings Calendar.ADMA’s Earnings Surprise HistoryADMA has an excellent track record. ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 105.63%. I ...